We are all in the same boat. Nasdaq listing in 2015 did not attract the Big Institutions into Oncosec stock like I thought it would. Hanging on for SITC data Nov. 2018 proved to be the wrong move as the data underwhelmed the market. So here we are waiting for PISCES approval and hopes for greater interest with car-t program and also the next-gen platform of TAVO and VLA for deeper tumor indications. All very exciting stuff of course, the science is very good but money is the issue. Partnering for car-t with cash via a licensing deal with Big Pharma or Big Biotech would do the trick here. It is very possible. The fact that Oncosec sent out the proxyvote this morning should at least let investors know Oncosec is giving them plenty of time to think and vote on the two proposals and not trying to get this vote passed in a sneeky was last minute.
News 
Market Data 
Discover 
AI
